Dundas Partners LLP Boosts Stock Holdings in Zoetis Inc. $ZTS

Dundas Partners LLP raised its stake in Zoetis Inc. (NYSE:ZTS) by 57.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 310,676 shares of the company’s stock after purchasing an additional 112,929 shares during the quarter. Zoetis comprises approximately 3.2% of Dundas Partners LLP’s holdings, making the stock its 16th biggest holding. Dundas Partners LLP owned approximately 0.07% of Zoetis worth $45,458,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Private Advisor Group LLC increased its holdings in shares of Zoetis by 9.0% during the 3rd quarter. Private Advisor Group LLC now owns 29,076 shares of the company’s stock worth $4,254,000 after buying an additional 2,404 shares during the last quarter. PFG Advisors boosted its holdings in Zoetis by 3.5% in the third quarter. PFG Advisors now owns 12,839 shares of the company’s stock valued at $1,879,000 after acquiring an additional 439 shares during the last quarter. Altman Advisors Inc. boosted its holdings in Zoetis by 1.0% in the third quarter. Altman Advisors Inc. now owns 9,297 shares of the company’s stock valued at $1,360,000 after acquiring an additional 94 shares during the last quarter. Prevail Innovative Wealth Advisors LLC purchased a new stake in Zoetis during the third quarter valued at about $4,378,000. Finally, Rathbones Group PLC increased its stake in Zoetis by 5.5% during the third quarter. Rathbones Group PLC now owns 532,064 shares of the company’s stock worth $77,852,000 after acquiring an additional 27,590 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective on the stock. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. BTIG Research restated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, KeyCorp initiated coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

Shares of NYSE ZTS opened at $121.54 on Monday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a market capitalization of $51.31 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.85 and a beta of 0.95. The business has a 50-day moving average of $126.06 and a 200-day moving average of $132.88.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.